The prevention of coronary heart disease in women

Karen L. Margolis; Kristine Ensrud; Maria Maldonado; Pamela Charney; Tom Clayton; Janet Rich-Edwards; Joann Manson; Charles Hennekens; Julie Buring

doi:10.1056/NEJM199512073332315

The prevention of coronary heart disease in women

Karen L. Margolis, Kristine Ensrud, Maria Maldonado, Pamela Charney, Tom Clayton, Janet Rich-Edwards, Joann Manson, Charles Hennekens, Julie Buring

Research output: Contribution to journal › Letter › peer-review

1 Scopus citations

Abstract

To the Editor: Lipid-lowering drugs are generally expensive and frequently have bothersome side effects. Although primary-prevention trials have shown that lipid-lowering therapy can reduce the incidence of coronary heart disease in middle-aged men, meta-analysis of these trials has shown no effect of this type of therapy on overall survival.¹ Concern about serious adverse effects of lipid-lowering drugs has prompted some to urge caution in their use in healthy, asymptomatic people.² Although the Journal's recent review of primary prevention of coronary heart disease in women (June 29 issue)³ does not directly advocate the use of lipid-lowering drugs in women, we.

Original language	English (US)
Pages (from-to)	1570-1572
Number of pages	3
Journal	New England Journal of Medicine
Volume	333
Issue number	23
DOIs	https://doi.org/10.1056/NEJM199512073332315
State	Published - Dec 7 1995
Externally published	Yes

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access

10.1056/NEJM199512073332315

OpenUrl availability

Full text

Cite this

@article{81eb4fbc18fb4f259fe827d2df266ce4,

title = "The prevention of coronary heart disease in women",

abstract = "To the Editor: Lipid-lowering drugs are generally expensive and frequently have bothersome side effects. Although primary-prevention trials have shown that lipid-lowering therapy can reduce the incidence of coronary heart disease in middle-aged men, meta-analysis of these trials has shown no effect of this type of therapy on overall survival.1 Concern about serious adverse effects of lipid-lowering drugs has prompted some to urge caution in their use in healthy, asymptomatic people.2 Although the Journal's recent review of primary prevention of coronary heart disease in women (June 29 issue)3 does not directly advocate the use of lipid-lowering drugs in women, we.",

author = "Margolis, {Karen L.} and Kristine Ensrud and Maria Maldonado and Pamela Charney and Tom Clayton and Janet Rich-Edwards and Joann Manson and Charles Hennekens and Julie Buring",

year = "1995",

month = dec,

day = "7",

doi = "10.1056/NEJM199512073332315",

language = "English (US)",

volume = "333",

pages = "1570--1572",

journal = "New England Journal of Medicine",

issn = "0028-4793",

publisher = "Massachussetts Medical Society",

number = "23",

}

TY - JOUR

T1 - The prevention of coronary heart disease in women

AU - Margolis, Karen L.

AU - Ensrud, Kristine

AU - Maldonado, Maria

AU - Charney, Pamela

AU - Clayton, Tom

AU - Rich-Edwards, Janet

AU - Manson, Joann

AU - Hennekens, Charles

AU - Buring, Julie

PY - 1995/12/7

Y1 - 1995/12/7

N2 - To the Editor: Lipid-lowering drugs are generally expensive and frequently have bothersome side effects. Although primary-prevention trials have shown that lipid-lowering therapy can reduce the incidence of coronary heart disease in middle-aged men, meta-analysis of these trials has shown no effect of this type of therapy on overall survival.1 Concern about serious adverse effects of lipid-lowering drugs has prompted some to urge caution in their use in healthy, asymptomatic people.2 Although the Journal's recent review of primary prevention of coronary heart disease in women (June 29 issue)3 does not directly advocate the use of lipid-lowering drugs in women, we.

AB - To the Editor: Lipid-lowering drugs are generally expensive and frequently have bothersome side effects. Although primary-prevention trials have shown that lipid-lowering therapy can reduce the incidence of coronary heart disease in middle-aged men, meta-analysis of these trials has shown no effect of this type of therapy on overall survival.1 Concern about serious adverse effects of lipid-lowering drugs has prompted some to urge caution in their use in healthy, asymptomatic people.2 Although the Journal's recent review of primary prevention of coronary heart disease in women (June 29 issue)3 does not directly advocate the use of lipid-lowering drugs in women, we.

UR - http://www.scopus.com/inward/record.url?scp=0029638959&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029638959&partnerID=8YFLogxK

U2 - 10.1056/NEJM199512073332315

DO - 10.1056/NEJM199512073332315

M3 - Letter

C2 - 7477188

AN - SCOPUS:0029638959

SN - 0028-4793

VL - 333

SP - 1570

EP - 1572

JO - New England Journal of Medicine

JF - New England Journal of Medicine

IS - 23

ER -

The prevention of coronary heart disease in women

Abstract

UN SDGs

Access

OpenUrl availability

Other files and links

Fingerprint

Cite this